

FILE 'CAPLUS' ENTERED AT 14:52:39 ON 29 JUN 1999  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 1999 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 29 Jun 1999 VOL 131 ISS 1  
FILE LAST UPDATED: 29 Jun 1999 (19990629/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 176591-03-0/rn

1 176591-03-0  
0 176591-03-0D  
L3 1 176591-03-0/RN  
(176591-03-0 (NOTL) 176591-03-0D )

=> d bib ab

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 1999 ACS  
AN 1996:295079 CAPLUS  
DN 124:352673  
TI Recombinant production and purification of hepatitis C virus envelope proteins for diagnostic and therapeutic use  
IN Maertens, Geert; Bosman, Fons; De Martynoff, Guy; Buyse, Marie-Ange  
PA Innogenetics N.V., Belg.  
SO PCT Int. Appl., 146 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9604385	A2	19960215	WO 95-EP3031	19950731
	WO 9604385	A3	19960307		
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA			
	RW:	KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2172273	AA	19960215	CA 95-2172273	19950731
	AU 9533824	A1	19960304	AU 95-33824	19950731
	EP 721505	A1	19960717	EP 95-930434	19950731
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,			
SE	JP 09503396	T2	19970408	JP 95-506189	19950731

BR 9506059            A    19971028            BR 95-6059            19950731  
PRAI EP 94-870132       19940729  
WO 95-EP3031           19950731  
AB    Envelope proteins E1 and E2 of hepatitis C virus (HCV), their recombinant  
      prodn. and purifn., their fragments and engineered derivs., their  
      antigenic epitope peptides, their monoclonal antibodies, and their use  
for  
      diagnostic and therapeutic means are provided. A method is described for  
      purifying recombinant HCV single or specific oligomeric envelope  
proteins,  
      characterized in that upon lysing the transformed host cells to isolate  
      the recombinantly expressed protein a disulfide bond cleavage or redn.  
      step is carried out with a disulfide bond cleavage agent (such as  
      dithiothreitol and/or Empigen BB) and an SH group protecting agent (such  
      as N-ethylmaleimide). Various forms of the E1 and E2 proteins are  
      constructed by std. genetic techniques using vaccinia virus recombination  
      vectors; such proteins are specific for various HCV genotypes, may delete  
      the hydrophobic region from E1, or remove various glycosylation sites;  
      they may also add factor Xa cleavage sites and His6 tags for improved  
      purifn. Epitope (such as F, G, H, and I) peptides are used to generate  
      monoclonal antibodies and to monitor disease progression in patients.  
      Furthermore, the HCV E1 protein and peptides are used for prognosing and  
      monitoring the clin. effectiveness and/or clin. outcome of HCV treatment.

=> log h

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.70	40.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.54	-0.54

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 14:54:19 ON 29 JUN 1999

08/928757

SEQ ID 53

=> s yevrnvsgiyhvtndcsnssivyeaadmimhtpgcgk/sqsp

L1 1 YEVRNVSGIYHVTNDCSNSSIVYEADMIMHTPGCGK/SQSP

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1999 ACS  
RN 176591-03-0 REGISTRY  
CN L-Lysine, L-tyrosyl-L-.alpha.-glutamyl-L-valyl-L-arginyl-L-asparaginyl-L-  
valyl-L-serylglycyl-L-isoleucyl-L-tyrosyl-L-histidyl-L-valyl-L-threonyl-L-  
asparaginyl-L-.alpha.-aspartyl-L-cysteiny-L-seryl-L-asparaginyl-L-seryl-L-  
seryl-L-isoleucyl-L-valyl-L-tyrosyl-L-.alpha.-glutamyl-L-alanyl-L-alanyl-L-  
.alpha.-aspartyl-L-methionyl-L-isoleucyl-L-methionyl-L-histidyl-L-threonyl-  
L-prolylglycyl-L-cysteinyglycyl- (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE  
MF C172 H266 N48 O58 S4  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXLIT

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1967 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> d sqd

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1999 ACS  
RN 176591-03-0 REGISTRY  
FS PROTEIN SEQUENCE  
SQL 37

SEQ 1 YEVRNVSGIY HVTNDCSNSS IVYEADMIM HTPGCGK  
=====

HITS AT: 1-37

=> s yevrnvsgiyhvtndcsnssivyeaadmimhtpgcgk/sqefp

1 YEVRNVSGIYHVTNDCSNSSIVYEADMIMHTPGCGK/SQEFP  
3533 SQL=37  
L2 1 YEVRNVSGIYHVTNDCSNSSIVYEADMIMHTPGCGK/SQEFP  
(YEVRNVSGIYHVTNDCSNSSIVYEADMIMHTPGCGK/SQEFP AND SQL=37)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL  
ENTRY SESSION

For Ref  
EP388232

L1 ANSWER 38 OF 38 REGISTRY COPYRIGHT 2000 ACS  
RN 133403-44-8 REGISTRY  
FS PROTEIN SEQUENCE  
SQL 51

SEQ 1 ALAHGVRVLE DGVNYATGNL PGCSFSIFLL ALLSCLTVPA SAYQVRNSTG  
=====

51 L

=

HITS AT: 32-51

1/24/00  
4 pgs

=&gt; s 133403-44-8/rn

1 133403-44-8  
 0 133403-44-8D  
 L3 1 133403-44-8/RN  
 (133403-44-8 (NOTL) 133403-44-8D )

=&gt; d bib ab

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2000 ACS  
 AN 1991:222815 CAPLUS  
 DN 114:222815  
 TI Cloning and expression of partial cDNA sequences of hepatitis virus C,  
 purification of the protein products, and their use as diagnostics and  
 vaccines  
 IN Houghton, Michael; Choo, Qui Lim; Kuo, George  
 PA Chiron Corp., USA  
 SO Eur. Pat. Appl., 84 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 388232	A1	19900919	EP 1990-302866	19900316
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	WO 9011089	A1	19901004	WO 1990-US1348	19900315
	W: AU, FI, HU, JP, KR, NO, SU				
	AU 9052783	A1	19901022	AU 1990-52783	19900315
	AU 640920	B2	19930909		
	HU 54896	A2	19910429	HU 1990-2814	19900315
	JP 04504715	T2	19920820	JP 1990-505094	19900315
	JP 09215497	A2	19970819	JP 1996-237015	19900315
	JP 10295389	A2	19981110	JP 1998-93768	19900315
	JP 10309197	A2	19981124	JP 1998-93767	19900315
	JP 2000039434	A2	20000208	JP 1999-157192	19900315
	DD 297446	A5	19920109	DD 1990-338836	19900316
	EP 1034785	A2	20000913	EP 2000-109602	19900316
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	CA 2012482	AA	19900917	CA 1990-2012482	19900319
	EP 414475	A1	19910227	EP 1990-309120	19900821
	EP 414475	B1	19971210		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 161041	E	19971215	AT 1990-309120	19900821
	ES 2110411	T3	19980216	ES 1990-309120	19900821
	CA 2064705	AA	19910226	CA 1990-2064705	19900822
	CA 2064705	C	19990406		
	WO 9102820	A1	19910307	WO 1990-US4766	19900822
	W: AU, CA, JP				
	AU 9063449	A1	19910403	AU 1990-63449	19900822
	AU 655156	B2	19941208		
	JP 05502156	T2	19930422	JP 1990-512531	19900822
	NO 9004712	A	19901030	NO 1990-4712	19901030
	WO 9115771	A1	19911017	WO 1991-US2225	19910329
	W: AU, BB, BG, BR, CA, FI, GB, HU, JP, KP, KR, LK, MC, MG, MW, NO, PL, RO, SD, SU				
	RW: BF, BJ, CF, CG, CM, GA, ML, MR, SN, TD, TG				
	AU 9176510	A1	19911030	AU 1991-76510	19910329
	AU 639560	B2	19930729		
	GB 2257784	A1	19930120	GB 1992-20480	19910329

BR 9106309	A	19930420	BR 1991-6309	19910329
HU 62706	A2	19930528	HU 1992-3146	19910329
HU 217025	B	19991129		
JP 05508219	T2	19931118	JP 1991-507636	19910329
JP 2733138	B2	19980330		
RO 109916	B1	19950728	RO 1975-92012	19910329
PL 172133	B1	19970829	PL 1991-296329	19910329
RU 2130969	C1	19990527	RU 1991-5053084	19910329
EP 450931	A1	19911009	EP 1991-302910	19910403
EP 450931	B1	19960612		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
EP 693687	A1	19960124	EP 1995-114016	19910403
EP 693687	B1	19990728		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 139343	E	19960615	AT 1991-302910	19910403
ES 2088465	T3	19960816	ES 1991-302910	19910403
AT 182684	E	19990815	AT 1995-114016	19910403
ES 2134388	T3	19991001	ES 1995-114016	19910403
US 5683864	A	19971104	US 1992-910760	19920707
NO 9203839	A	19921119	NO 1992-3839	19921001
US 5714596	A	19980203	US 1993-40564	19930331
LV 10344	B	19960220	LV 1993-4381	19930531
US 5679342	A	19971021	US 1993-97853	19930727
US 5350671	A	19940927	US 1993-103961	19930809
AU 9347505	A1	19931216	AU 1993-47505	19930921
AU 666767	B2	19960222		
AU 9347506	A1	19931216	AU 1993-47506	19930921
AU 666576	B2	19960215		
AU 9347504	A1	19940120	AU 1993-47504	19930921
AU 666766	B2	19960222		
LT 3808	B	19960325	LT 1993-1747	19931230
JP 07101986	A2	19950418	JP 1994-12988	19940204
JP 07145194	A2	19950606	JP 1994-61370	19940330
US 5698390	A	19971216	US 1994-306472	19940915
US 6074816	A	20000613	US 1994-307273	19940916
US 5968775	A	19991019	US 1995-438435	19950510
US 5712087	A	19980127	US 1995-440519	19950512
US 5712088	A	19980127	US 1995-440769	19950515
US 6027729	A	20000222	US 1995-440755	19950515
US 6096541	A	20000801	US 1995-441026	19950515
US 5863719	A	19990126	US 1995-472821	19950607
NO 9600741	A	19960223	NO 1996-741	19960223
NO 9600742	A	19960223	NO 1996-742	19960223
FI 9801381	A	19980615	FI 1998-1381	19980615
PRAI US 1989-325338		19890317		
US 1989-341334		19890420		
US 1989-355002		19890518		
US 1987-122714		19871118		
US 1987-139886		19871230		
US 1988-161072		19880226		
US 1988-191263		19880506		
US 1988-263584		19881026		
US 1988-271450		19881114		
WO 1988-US4125		19881118		
US 1989-353896		19890421		
US 1989-355961		19890518		
US 1989-398667		19890825		
US 1989-456637		19891221		
JP 1990-505094		19900315		
JP 1996-237015		19900315		
JP 1998-93767		19900315		
WO 1990-US1348		19900315		
EP 1990-302866		19900316		
US 1990-504352		19900404		
US 1990-505435		19900404		
US 1990-566209		19900808		

WO 1990-US4766	19900822
NO 1990-4712	19901030
US 1990-611965	19901108
WO 1991-US2225	19910329
EP 1991-302910	19910403
US 1992-910760	19920707
US 1993-40564	19930331
US 1993-97853	19930727
US 1993-103961	19930809
US 1994-306472	19940915

AB. A partial cDNA sequence of hepatitis virus C (HVC) is cloned and sequenced. Several open reading frames (ORF) are expressed and the protein products purified. The cDNA, the protein, and antibodies thereto can be used as diagnostics or vaccines (no data). CDNA clones for several ORF were isolated from a previously constructed .lambda.gt-11 library and a new pi library using synthetic DNA probes. An HVC cDNA sequence was compiled based on these clones. The epitopes manufd. by recombinant yeast or Escherichia coli were immunogenically reactive to the sera of the HVC-infected patients.

=> s 153299-59-3/rn

```

      1 153299-59-3
      1 153299-59-3D
L11    0 153299-59-3/RN
      (153299-59-3 (NOTL) 153299-59-3D )

```

=> s 153299-59-3

# REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L13 1 L12

=> d bib ab

L13 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2000 ACS

AN 1994:161617 CAPLUS

DN 120:161617

TI Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies, or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them

IN De Leys, Robert

PA N.V. Innogenetics S.A., Belg.

SO PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9318054	A2	19930916	WO 1993-EP517	19930308
	WO 9318054	A3	19940217		
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, NZ, PL, PT, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	EP 564746	A1	19931013	EP 1992-400598	19920306
	CA 2102301	AA	19930907	CA 1993-2102301	19930308
	AU 9337463	A1	19931005	AU 1993-37463	19930308
	AU 671623	B2	19960905		
	EP 589004	A1	19940330	EP 1993-906490	19930308
	EP 589004	B1	19990506		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 06505806	T2	19940630	JP 1993-515334	19930308
	BR 9305435	A	19941227	BR 1993-5435	19930308
	EP 891982	A2	19990120	EP 1998-202777	19930308
	EP 891982	A3	20000412		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	AT 179716	E	19990515	AT 1993-906490	19930308
	ES 2133392	T3	19990916	ES 1993-906490	19930308



US 5891640            A    19990406            US 1993-146028    19931122  
PRAI EP 1992-400598    19920306  
EP 1993-906490    19930308  
WO 1993-EP517    19930308

AB Peptides corresponding to immunol. important epitopes (of bacterial or viral proteins) are detd. by (1) prepg. peptides corresponding to fragments of the protein of interest, (2) biotinylating the peptides, (3) binding the biotinylated peptides to a solid phase via interaction with avidin or streptavidin, and (4) measuring antibodies which bind to the individual peptides. Processes for biotinylation of the peptides and for detn. of antibodies to hepatitis C virus (HCV), to HIV, and to HTLV-I and -II are also disclosed. HCV, HIV, HTLV-I, and HTLV-II peptide sequences are included. Use of the biotinylated peptides in the process of the invention makes the anchorage of the peptides to a solid support such that it leaves their essential amino acids free to be recognized by antibodies. In studies detg. binding of unbiotinylated peptides directly onto the wells of a polystyrene microtiter plate and binding of biotinylated peptides to wells coated with streptavidin, results demonstrated that antibody binding to the biotinylated peptide is superior to antibody binding to peptide coated directly onto the plastic.

SEQ ID NO 72

L7 ANSWER 6 OF 8 REGISTRY COPYRIGHT 2000 ACS  
RN 149119-56-2 REGISTRY  
FS PROTEIN SEQUENCE  
SQL 174

SEQ 1 IPQAILDMIA GAHWGVLAGI AYFSMVG NWA KVLVLLLF A GVDAETIVSG  
51 GQAARAMSGL VSLFTPGAKQ NIQLINTNGS WHINSTALNC NESLNTGWLA  
=====  
101 GLIYQHKFNS SGCPERLASC RRLTDFDQGW GPISHANGSG PDQRPYCWHY  
151 PPKPCGIVPA KSVCGPVYCF TPSP  
HITS AT: 58-77

for Ref

EP537626

2pgs

=&gt; s 149119-56-2/rn

1 149119-56-2  
 0 149119-56-2D  
 L14 1 149119-56-2/RN  
 (149119-56-2 (NOTL) 149119-56-2D )

=&gt; d bib ab

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2000 ACS  
 AN 1994:52649 CAPLUS  
 DN 120:52649  
 TI Diagnostic reagent for hepatitis C  
 IN Miyamura, Tatsuo; Saito, Izumu; Harada, Shizuko; Honda, Yoshikazu  
 PA National Institute of Health, Japan  
 SO Eur. Pat. Appl., 58 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 537626	A1	19930421	EP 1992-117191	19921008
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, PT, SE				
	JP 05142231	A2	19930608	JP 1991-260824	19911008
	CA 2080213	AA	19930409	CA 1992-2080213	19921008
	US 5750331	A	19980512	US 1994-325630	19941019
	US 5747241	A	19980505	US 1995-460806	19950602
PRAI	JP 1991-260824		19911008		
	US 1992-956993		19921006		
	US 1994-325630		19941019		

AB A diagnostic reagent for hepatitis C, which detects an antibody induced by infection with hepatitis C virus, is disclosed. The reagent comprises the 2nd envelope protein or 1st nonstructural protein encoded by the hepatitis C gene and has a sugar chain (E2/NS1 glycoprotein). A method for detecting anti-hepatitis C antibody is also disclosed. The reagent of the invention makes the highly sensitive diagnosis of hepatitis C possible. E2/NS1 glycoprotein amino acid sequences, and corresponding nucleotide sequences, are included. E2/NS1 cDNA was cloned and expressed. Cells (13L20), which constantly produced the E2/NS1 protein, were cultured, fixed, and reacted with 59 serum samples from hepatitis C patients and then with a secondary antibody. Fluorescence microscopy showed that 53 of the samples were pos.; of the 59 samples, 6 were pos. using CHO cells constantly producing the 1st envelope region of hepatitis C virus.

L7 ANSWER 3 OF 8 REGISTRY COPYRIGHT 2000 ACS  
RN 153299-61-7 REGISTRY  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 24

SEQ 1 ARAMSGLVSL FTPGAKQNIQ LINT  
=====

HITS AT: 5-24

W093/18054  
4 pgs

L7 ANSWER 4 OF 8 REGISTRY COPYRIGHT 2000 ACS  
RN 153299-59-3 REGISTRY  
FS PROTEIN SEQUENCE; STEREOSEARCH  
SQL 34

SEQ 1 AETIVSGGQA ARAMSGLVSL FTPGAKQNIQ LINT  
=====

HITS AT: 15-34